Blar i forfatter Det helsevitenskapelige fakultet "Helbekkmo, Nina"
-
Advanced Non-small Cell Lung Cancer Effects of Chemotherapy and Impact on Health Related Quality of Life
Helbekkmo, Nina (Doctoral thesis; Doktorgradsavhandling, 2009-03-13)Avhandlingen presenterer behandlingseffekt, bivirkninger og livskvalitet hos lungekreftpasienter som får moderne cellegiftbehandling. Pasientene med performance status (PS) 2 er etterpå vurdert separat. <br><br>Avhandlingens tittel er ”Advanced non-small cell Lung Cancer – Effects of Chemotherapy and Impact on Health Related Quality of Life”. Den ble forsvart for graden PhD 13.03.2009. På verdensbasis ... -
Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial
Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug; Rogg, Lotte Victoria (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-04)The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in ... -
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Fløtten, Øystein; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2013-08-20)Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved.<p> <p>Methods: Patients not eligible for curative radiotherapy were randomised to receive either chemoradiation or chemotherapy alone. Four courses of intravenous carboplatin on day 1 and oral ... -
Does chemotherapy improve Quality of Life in NSCLC PS 2?
Sundstrøm, Stein H.; Helbekkmo, Nina; von Plessen, Christian; Strøm, Hans H.; Aasebø, Ulf; Bremnes, Roy M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2009-03)Introduction <br>Nearly 40% of patients with advanced NSCLC are in performance status (PS) 2. These patients have a shorter life expectancy than PS 0/1 patients and they are underrepresented in clinical trials. Data on how platinum-based combination chemotherapy affects Health Related Quality of Life (HRQOL) of patients with PS 2 are scarce and the treatment of this important group of patients is ... -
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced NoneSmall Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-05)In a phase III trial of patients with unresectable stage III nonesmall-cell lung cancer and a poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided a significantly better outcome than chemotherapy alone, except among performance status 2 patients. The results of the present exploratory subgroup analysis indicate that elderly patients with poor prognosis can also experience ... -
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
Norum, Jan; Antonsen, Margaret Aarag; Tollåli, Geir; Al-Shibli, Khalid; Andersen, Gry; Svanqvist, Kristin-Helene; Helbekkmo, Nina (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-07-29)1 Norum J, et al . ESMO Open 2017; 2 :e000222. doi:10.1136/esmoopen-2017-000222 Open Access Abstr A ct Background P embrolizumab is a new drug approved in several countries for second-line therapy in non-small cell lung cancer (NSCLC) being programmed cell death ligand (PD-L1) positive. This drug has a high cost, and the cost- effectiveness ratio has been debated. Patients ... -
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
Strøm, Hans Henrik; Bremnes, Roy M.; Sundstrøm, Stein Harald; Helbekkmo, Nina; Aasebø, Ulf (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-11-20)Introduction: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL).<p> <p>Methods: ...